The first day of the U.S. FDA’s two-day advisory hearing on generative artificial intelligence reflected some of the ...

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular diseases that can be evident from the ...

Former U.S. FDA Commissioner Margaret Hamburg has added her voice to concerns that the incoming Trump administration’s pledge ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software ...

Medtronic plc and Tempus AI Inc. launched the ALERT study to better understand and address the racial, ethnic, gender and ...

Urocortin-2 (UCN2) is a selective corticotropin-releasing factor CRF2 receptor (CRFR2) agonist, which has been previously shown to reduce fat mass while promoting muscle hypertrophy. Hanmi ...

Researchers developed a novel electrochemical biosensor technology capable of assessing symmetric dimethylarginine to detect early kidney disease, which could be adapted to detect other biomarkers for ...

Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and ...

Chiome Bioscience Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement to develop and commercialize Chiome’s humanized anti-CX3CR1 antibody, PFKR, currently in the ...

Vaginal microbiome specialist Freya Bioscience ApS has added $11.8 million to its series A, bringing the total for the round ...

Researchers from Xencor Inc. described the preclinical characterization of XmAb-808.